Related Experiment Video
Updated: May 24, 2026

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
Published on: July 5, 2018
Analysis of binding sites on complement factor I using artificial N-linked glycosylation
Jose I Sanchez-Gallego1, Tom W L Groeneveld, Stefanie Krentz
1Department of Laboratory Medicine, Medical Protein Chemistry, Malmö University Hospital, Lund University, S-205 02 Malmö, Sweden.
Insights
Factor I (FI) regulates complement pathways by degrading C3b and C4b. Mutations in its FIMAC and SP domains significantly impair this function, highlighting their crucial role.
Area of Science:
- Immunology
- Proteomics
- Biochemistry
Background:
- Factor I (FI) is a serine protease essential for inhibiting complement pathways.
- FI degrades activated complement components C3b and C4b, requiring cofactors like Factor H.
- FI comprises a light chain (serine protease domain) and a heavy chain (FIMAC, CD5, LDLr1/2 domains).
Purpose of the Study:
- To elucidate the functional importance of different Factor I domains in complement regulation.
- To identify key protein-protein interaction sites within Factor I using homology modeling and mutagenesis.
- To understand how mutations affect FI's cofactor-dependent degradation of C3b and C4b.
Main Methods:
- Homology-based three-dimensional modeling of Factor I domains.
- Site-directed mutagenesis to create 20 recombinant FI mutants with altered glycosylation sites.
- Biochemical assays measuring FI's degradation of C3b and C4b in fluid and surface phases with various cofactors.
Main Results:
- Mutations in the FIMAC and SP domains severely inhibited FI's ability to degrade C3b and C4b, regardless of the cofactor.
- Alterations in the CD5 and LDLr1/2 domains had a less significant impact on FI's degradation activity.
- The Michaelis constant (K(m)) for small substrates remained unchanged in all mutants.
Conclusions:
- The FIMAC and SP domains are critical for Factor I's enzymatic activity in complement regulation.
- Cofactors likely form similar complexes with FI and C3b/C4b, emphasizing the importance of domain accessibility.
- Accessible FIMAC and SP domains are essential for the proper function of Factor I in inhibiting complement.
Abstract:
Factor I (FI) is a serine protease that inhibits all complement pathways by degrading activated complement components C3b and C4b. FI functions only in the presence of several cofactors, such as factor H, C4b-binding protein, complement receptor 1, and membrane cofactor protein. FI is composed of two chains linked by a disulfide bridge; the light chain comprises only the serine protease (SP) domain, whereas the heavy chain contains the FI membrane attack complex domain (FIMAC), CD5 domain, and low density lipoprotein receptor 1 (LDLr1) and LDLr2 domains. To better understand how FI inhibits complement, we used homology-based three-dimensional models of FI domains in an attempt to identify potential protein-protein interaction sites. Specific amino acids were then mutated to yield 20 recombinant mutants of FI carrying additional surface-exposed N-glycosylation sites that were expected to sterically hinder interactions. The Michaelis constant (K(m)) of all FI mutants toward a small substrate was not increased. We found that many mutations in the FIMAC and SP domains nearly abolished the ability of FI to degrade C4b and C3b in the fluid phase and on the surface, irrespective of the cofactor used. On the other hand, only a few alterations in the CD5 and LDLr1/2 domains impaired this activity. In conclusion, all analyzed cofactors form similar trimolecular complexes with FI and C3b/C4b, and the accessibility of FIMAC and SP domains is crucial for the function of FI.
Related Concept Videos
Protein Glycosylation
Glycosylation occurs in...
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Ligand Binding and Linkage

